×
Choose Speciality

EXPLORE!

LOGIN

Evolving Gliptin - Evogliptin

  1020 Views

Dr Awadhesh K Singh, Kolkata    21 November 2018

  1. Evogliptin (DA-1229) is a piperazine derivative. It is a selective, potent and reversible inhibitor of DPP-4.
  2. The agent has been studied in a Phase II study and two Phase III studies in South Korea in T2DM patients.
  3. According to a recent study, evogliptin 5 mg monotherapy significantly decreased HbA1c and was well-tolerated in patients with T2DM inadequately controlled on diet and exercise.
  4. The results suggested that T2DM patients with modest hyperglycemia may be good candidates for evogliptin monotherapy.
  5. Evogliptin 5 mg added to metformin therapy has been found to improve glycemic control and was non-inferior to sitagliptin and well-tolerated in T2DM patients inadequately controlled by metformin alone. Evogliptin is a weight-neutral agent and has minimal potential for drug interactions. It can be used safely in patients with renal dysfunction.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.